January 14, 2020

We saw lots of action in the biopharma merger and acquisition (M&A) space in 2019, headlined by Bristol-Myers Squibb acquiring Celgen...

November 24, 2019

We proudly introduce the newest addition to the Visicell family, the Visicell Board of Advisors: 

George Smith, PhD, MBA

Director,...

June 11, 2019

Almost 10 years after this was first observed, a second patient has now gone into remission for HIV after receiving a stem cell trans...

June 11, 2019

It is clear that there is a need for safety regulation in the cell therapy market. This article discusses the need for increased regu...

April 15, 2019

According to a Nature article, the Japanese health ministry is expected to soon decide on a reprogrammed stem cell therapy for damage...

April 15, 2019

The FDA has stepped up its enforcement on unapproved therapies in many stem cell clinics across the United States. With false promise...

April 15, 2019

A partnership between Dan Kauffman, MD, PhD, at the Sanford Consortium of Regenerative Medicine, local biotech Fate Pharmaceuticals,...

March 6, 2019

Visicell visited California Institute of Regenerative medicine (CIRM) and presented their recent development on non-invasive cell tra...

February 28, 2019

Visicell had recently joined HESI CT-TRACS, a global committee with multiple stakeholders ranging from academic institutions, biotech...

November 30, 2018

Visicell is proud recipient of a grant from StartR Inclusion (formerly known as mystartupXX), and is grateful for StartR's continued...

Please reload

Our Recent Posts

Please reload

Archive

Please reload

Tags

Please reload